Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Help H. Lundbeck Reposition, Develop Shelved Drug Candidates

NEW YORK (GenomeWeb News) — Gene Logic yesterday said it will help H. Lundbeck reposition and develop certain drugs candidates that were “discontinued” or “de-prioritized” for reasons other than safety.
 
Gene Logic said the deal allows for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lundbeck's contribution as the originator of the compound.
 
It also provides an option to license any of the candidates that Lundbeck decides not to pursue, in which case Lundbeck would receive success-based milestone and royalty payments.
 
Financial details were not disclosed.
 
Gene Logic also said yesterday that it expects to pocket around $2.5 million from Lundbeck over the coming year from an unrelated technology licensing agreement.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.